NASDAQ: AXNXAxonics Inc Stock
$66.84-0.11 (-0.16%)
Updated Apr 22, 2024
AXNX Price
$66.84
Fair Value Price
N/A
Market Cap
$3.41B
52 Week Low
$47.59
52 Week High
$69.68
P/E
-557x
P/B
5.35x
P/S
8.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$366.38M
Earnings
-$6.09M
Gross Margin
74.9%
Operating Margin
-2.56%
Profit Margin
-1.7%
Debt to Equity
0.13
Operating Cash Flow
-$2M
Beta
1.16
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AXNX Overview
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AXNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AXNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AXNX is poor value based on its book value relative to its share price (5.35x), compared to the US Medical Devices industry average (3.65x)
P/B vs Industry Valuation
AXNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AXNX due diligence checks available for Premium users.
Be the first to know about important AXNX news, forecast changes, insider trades & much more!
AXNX News
Valuation
AXNX fair value
Fair Value of AXNX stock based on Discounted Cash Flow (DCF)
Price
$66.84
Fair Value
-$0.19
Undervalued by
35,358.05%
AXNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AXNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-557x
Industry
29.12x
Market
41x
AXNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.35x
Industry
3.65x
AXNX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AXNX's financial health
Profit margin
Revenue
$109.7M
Net Income
$6.6M
Profit Margin
6%
AXNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AXNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$719.9M
Liabilities
$82.4M
Debt to equity
0.13
AXNX's short-term assets ($491.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AXNX's short-term assets ($491.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AXNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AXNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$5.6M
Investing
-$37.9M
Financing
$578.0k
AXNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AXNX vs Medical Device Stocks
Axonics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.